Angiomax® (bivalirudin) FOR INJECTION

Print This Page

Tell a Colleague

Prescribing Information

About ANGIOMAX

Clinical Information

About PCI

Bleeding – a Predictor
of Mortality

About HIT/HITTS

Removal of the Femoral
Arterial Catheter

Medical Information

Helpful Resources

ANGIOMAX Key Events at:

Mode of Action Video

See a vivid demonstration of ANGIOMAX in action. Watch ANGIOMAX: Thrombin-Specific Inhibition for Preventing Thrombosis and Thrombin-Mediated Platelet Activation.

This content requires the Macromedia Flash Player. You may download the Flash Player here.

Angiomax® (bivalirudin) is an anticoagulant currently approved in the US and other countries for use in patients undergoing percutaneous coronary intervention, and in patients with or at risk for heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI.

ANGIOMAX works by directly inhibiting thrombin, a key factor involved in the formation of blood clots, to help prevent clot formation during PCI.

ANGIOMAX does not generate heparin antibodies, posing no risk of heparin-induced thrombocytopenia or thrombosis syndrome (HIT/HITTS).

Safety Considerations

ANGIOMAX with provisional use of glycoprotein IIb/IIIa inhibitor is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), and in patients with or at risk for heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI. ANGIOMAX is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin. ANGIOMAX is contraindicated in patients with active major bleeding or hypersensitivity to ANGIOMAX or its components. The most common (

10%) adverse events for ANGIOMAX were back pain, pain, nausea, headache, and hypotension. An unexplained fall in blood pressure or hematocrit, or any unexplained symptom, should lead to serious consideration of a hemorrhagic event and cessation of ANGIOMAX administration. Please see complete prescribing information.